Praxis Precision Medicines' Ulixacaltamide HCL Study 1 For Essential Tremor, Met Primary Endpoint, All Key Secondary Endpoints In Study 1 Were Also Statistically Significant

+30.54%

PRAXIS PRECISION MEDICINES, INC.

PRAX

247.99

+30.54%

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 points (p<0.0001)
All key secondary endpoints in Study 1 - rate of disease improvement over 12 weeks, PGI-C and CGI-S - were also statistically significant (p<0.001)
Study 2 met its pre-specified primary endpoint, with patients showing superior maintenance of effect while on ulixacaltamide versus placebo during the randomized-withdrawal phase (p=0.0369)
The first key secondary endpoint in Study 2 - rate of disease improvement during the randomized-withdrawal phase - also demonstrated superior effect in ulixacaltamide treated patients versus placebo (p=0.0042)
Ulixacaltamide was generally well tolerated with a safety profile consistent with previous trials and no drug-related serious adverse events
Praxis has submitted a pre-NDA meeting request to the FDA

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.